Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

Abstract Background One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical signif...

Full description

Bibliographic Details
Main Authors: Jacob Tveiten Bjerrum, Casper Steenholdt, Mark Ainsworth, Ole Haagen Nielsen, Michelle AC Reed, Karen Atkins, Ulrich Leonhard Günther, Fuhua Hao, Yulan Wang
Format: Article
Language:English
Published: BMC 2017-10-01
Series:BMC Medicine
Subjects:
Crohn’s disease
Diagnostics
Metabolomics
Serum
Ulcerative colitis
Online Access:http://link.springer.com/article/10.1186/s12916-017-0949-7

Internet

http://link.springer.com/article/10.1186/s12916-017-0949-7

Similar Items